Market open
Inozyme Pharma/INZY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inozyme Pharma
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Ticker
INZY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
59
Website
Inozyme Pharma Metrics
BasicAdvanced
$376M
Market cap
-
P/E ratio
-$1.46
EPS
1.52
Beta
-
Dividend rate
Price and volume
Market cap
$376M
Beta
1.52
52-week high
$7.80
52-week low
$2.69
Average daily volume
290K
Financial strength
Current ratio
9.842
Quick ratio
9.299
Long term debt to equity
48.455
Total debt to equity
49.47
Interest coverage (TTM)
-18.75%
Management effectiveness
Return on assets (TTM)
-37.87%
Return on equity (TTM)
-88.56%
Valuation
Price to book
3.93
Price to tangible book (TTM)
3.93
Price to free cash flow (TTM)
-4.245
Growth
Earnings per share change (TTM)
-5.25%
3-year earnings per share growth (CAGR)
-19.83%
What the Analysts think about Inozyme Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Inozyme Pharma stock.
Inozyme Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Inozyme Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Inozyme Pharma News
AllArticlesVideos
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Benzinga·4 days ago
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
GlobeNewsWire·3 weeks ago
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Inozyme Pharma stock?
Inozyme Pharma (INZY) has a market cap of $376M as of September 16, 2024.
What is the P/E ratio for Inozyme Pharma stock?
The price to earnings (P/E) ratio for Inozyme Pharma (INZY) stock is 0 as of September 16, 2024.
Does Inozyme Pharma stock pay dividends?
No, Inozyme Pharma (INZY) stock does not pay dividends to its shareholders as of September 16, 2024.
When is the next Inozyme Pharma dividend payment date?
Inozyme Pharma (INZY) stock does not pay dividends to its shareholders.
What is the beta indicator for Inozyme Pharma?
Inozyme Pharma (INZY) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.